People | May 23, 2021
Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The agreement will help ensure wider reach and access to patients in India
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
The vaccine was 85 percent effective in preventing severe disease across all regions.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Subscribe To Our Newsletter & Stay Updated
